← Leaderboards
Goldy C George
University Of Tx Md Anderson Can Ctr
$776,699
Attributed
$1,797,397
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $366K · FY2019–25$500K$375K$250K$125K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,797,397 · 1
By mechanism
R01$1,797,397 · 1
Top collaborators
- David S. Hong6 shared
- Tito R Mendoza2 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Ronald Anthony Depinho$97,148,322
- Kathrin Milbury$8,852,386
- Anil K Sood$29,572,737
- Peter W Pisters$146,474
- Ahmed Kaseb$3,699,074
Others in their field
Other Emerging Leaders on “Dizziness”
- Cecile Feldman · Rbhs-School Of Dental Medicine$11,278,781
- Qiuping Gu · National Institute On Deafness And Other Communication Disorders$6,033,987
- Sung Han · Salk Institute For Biological Studies$5,194,676
- Kathleen E Cullen · Jackson Laboratory$4,576,168
- Sara P.d. Chrisman · Seattle Children'S Hospital$3,160,318
- Charles Edward Leonard · University Of Pennsylvania$2,390,386
Research focus
DizzinessDoseAdverse EventDetectionDiarrheaDeteriorationArthralgiaBackAffectAcuteAftercareAdvanced Malignant NeoplasmClinical TreatmentAntineoplastic AgentsCohortColitisCombination ImmunotherapyCombined Modality TherapyCommunity Clinical Oncology ProgramCancer ImmunotherapyCoupledCancer TherapyDecision MakingDrug Development
Grant awards (6)
Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy$218,645
R01 · FY2025 · CA · contact PI
Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy$341,315
R01 · FY2024 · CA · contact PI
Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy$146,757
R01 · FY2023 · CA · contact PI
Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy$358,680
R01 · FY2022 · CA · contact PI
Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy$366,000
R01 · FY2020 · CA
Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy$366,000
R01 · FY2019 · CA